Hyper-CVAD and Sequential Blinatumomab for Newly Diagnosed Philadelphia Chromosome–Negative B-ALL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial
Lancet Haematol 2022 Oct 21;[EPub Ahead of Print], E Jabbour, NJ Short, N Jain, PA Thompson, TM Kadia, A Ferrajoli, X Huang, M Yilmaz, Y Alvarado, KP Patel, G Garcia-Manero, W Macaron, R Garris, M Konopleva, F Ravandi, H KantarjianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.